Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium Pharmaceutical (Nasdaq: COLL) said management will participate in two investor events in mid-April 2026: a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference and an in-person presentation at the Piper Sandler Spring Biopharma Symposium.
The Needham fireside chat is scheduled for April 15, 2026 at 2:15 p.m. ET with a live webcast and a replay archived on the company's investor website for 90 days. Piper Sandler engagement is on April 16, 2026 in Boston.
Collegium (Nasdaq: COLL) will acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with up to $135 million in contingent milestone payments. The deal is expected to close in Q2 2026, be immediately accretive to adjusted EBITDA, and deliver pro forma AZSTARYS net revenue of over $50 million in H2 2026.
Funding combines cash on hand and a $300 million delayed draw term loan; AZSTARYS is supported by patents into December 2037. Closing is subject to customary regulatory and HSR approvals.
Collegium (Nasdaq: COLL) will present two real-world data posters at PainConnect 2026, AAPM's annual meeting in Salt Lake City, March 5-8, 2026. The posters, presented March 6 on TV 1 at The Grand America Hotel, analyze buprenorphine real-world use and urine drug testing.
Presentations by Jody L. Green, PhD, highlight nonmedical use rates and presence of illicit drugs among patients treated with buprenorphine versus full agonist opioids. Important safety and approved-use information for BELBUCA (buprenorphine buccal film) is also included.
Collegium Pharmaceutical (Nasdaq: COLL) and Paris Hilton launched the "Embrace Your Sparkle" campaign on March 3, 2026 to raise awareness and destigmatize ADHD. Paris shares her personal ADHD journey and describes using JORNAY PM—an evening-dosed methylphenidate formulation—to support morning functioning and daytime symptom control.
The campaign promotes discussion with healthcare providers about individualized ADHD treatment plans and directs audiences to jornaypm.com/embrace-your-sparkle for resources.
Collegium (Nasdaq: COLL) will participate in multiple investor conferences the week of March 9–11, 2026 in Miami, FL, including Leerink Partners Global Healthcare, Jefferies Biotech on the Beach, The Citizens Life Sciences Conference, and a Barclays fireside chat on March 11 at 9:00 a.m. ET.
A live webcast of the Barclays fireside chat will be available via the Investors section of the company website and a replay will be archived for 90 days.
Collegium (Nasdaq: COLL) reported strong 2025 results: product revenues $780.6M (+24% YoY) and record quarterly revenues of $205.4M (+13% YoY). Jornay PM reached $148.9M for FY 2025 (+48% YoY) and $45.9M in the quarter (+57% YoY). Adjusted EBITDA was $460.5M (+15% YoY). The company exited 2025 with $386.7M in cash and reaffirmed 2026 guidance: Product Revenues $805–825M; Jornay PM $190–200M; Adjusted EBITDA $455–475M.
Boston Legacy FC announced a multi-year partnership with Collegium Pharmaceutical (NASDAQ: COLL) to sponsor the Collegium Sensory Room. The rooms will be available at Gillette Stadium and Centreville Bank Stadium in 2026 and at White Stadium beginning in 2027.
The sensory rooms, designed with CHADD input, provide quieter, regulated spaces for fans with sensory sensitivities and include branded signage, digital mentions, and community programming.
Collegium (Nasdaq: COLL) will report fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET the same day. An audio webcast will be available on the Investors section of the company website and replayable approximately two hours after the event.
Collegium (Nasdaq: COLL) will present four real‑world data posters on its ADHD product Jornay PM at the APSARD Annual Conference, Jan 15–18, 2026, in San Diego.
Poster session: Jan 17, 2026, 11:45 a.m.–12:45 p.m. PT at Manchester Grand Hyatt, Seaport E. Posters (Nos. 73–76) cover dosing, comparative risks/benefits with Concerta, morning/evening functioning in youth, and depression/anxiety outcomes in adults.
Collegium (NASDAQ: COLL) provided 2026 financial guidance and a business update on Jan 8, 2026. The company expects product net revenues of $805M–$825M, Jornay PM net revenue of $190M–$200M, and adjusted EBITDA of $455M–$475M for full-year 2026. Collegium closed a $980M syndicated credit facility in December 2025, used in part to repay $581M of its prior term loan, yielding immediate annualized interest savings. The company also announced an authorized generic supply agreement with Hikma, with planned Nucynta ER AG launch in Q1 2026 and broader AG timing tied to third-party generics.